Novo Nordisk has been firmly thrust into the limelight given the kerfuffle that has accompanied the stellar showing of semaglutide for obesity, but much of the Danish drugmaker’s focus is to seek out innovation in the diabetes space that has been its bread and butter.
Novo Nordisk Still On The Lookout For Diabetes Innovations
The Denmark-based major intends to build on its heritage in diabetes and is keen to hear from innovators in a space where prevalence is on the rise but is not being served by improved new products.
More from Deals
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus